Precipio Inc PRPO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRPO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $6.33
- Day Range
- $6.06–6.17
- 52-Week Range
- $4.75–14.80
- Bid/Ask
- $6.05 / $6.17
- Market Cap
- $8.80 Mil
- Volume/Avg
- 3,604 / 5,263
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.53
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.precipiodx.com
Valuation
|
Metric
|
PRPO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.61 |
Price/Sales | 0.53 |
Price/Cash Flow | — |
Price/Earnings
PRPO
Financial Strength
|
Metric
|
PRPO
|
|---|---|
Quick Ratio | 0.89 |
Current Ratio | 1.17 |
Interest Coverage | −324.17 |
Quick Ratio
PRPO
Profitability
|
Metric
|
PRPO
|
|---|---|
Return on Assets (Normalized) | −30.26% |
Return on Equity (Normalized) | −41.08% |
Return on Invested Capital (Normalized) | −37.64% |
Return on Assets
PRPO
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Wqbzjjvpk | Mjfv | $209.3 Bil | |
DHR
| Danaher Corp | Cntdqrcbn | Dsrylj | $174.8 Bil | |
IQV
| IQVIA Holdings Inc | Kqdqgvz | Gdvqk | $41.3 Bil | |
IDXX
| IDEXX Laboratories Inc | Vkckvmrwg | Tqnkvt | $39.6 Bil | |
A
| Agilent Technologies Inc | Nvvllktz | Sdrjb | $39.2 Bil | |
MTD
| Mettler-Toledo International Inc | Hgmdqdlbw | Pfyfjzp | $25.5 Bil | |
ICLR
| Icon PLC | Yhzdqvqv | Jkfbsn | $24.6 Bil | |
ILMN
| Illumina Inc | Wtbdlsnc | Cyljhd | $18.6 Bil | |
WAT
| Waters Corp | Lchnkjpm | Stgdg | $18.0 Bil | |
LH
| Laboratory Corp of America Holdings | Tkpzysbf | Czyqx | $17.1 Bil |